It is reported that Canada is considering imposing export taxes on commodities such as uranium and oil to counter Trump's tariff threat. Canada is studying the imposition of export taxes on major commodities exported to the United States, including uranium, oil and potash, in the case that Trump fulfills the comprehensive tariff threat. Officials familiar with the internal discussions of Canadian Prime Minister Trudeau's government said that the export tax would be Canada's last resort. According to people familiar with the matter, retaliatory tariffs on goods made in the United States and export controls on some Canadian products are more likely to come first. However, these officials said that if Trump decides to launch a full-scale trade war, the commodity export tax is a practical option, which will push up the costs of American consumers, farmers and enterprises. They said that the Trudeau government may also propose to expand its export control power in the latest report on the country's financial and economic situation scheduled to be released on Monday. It is reported that Canada is currently the largest external oil supplier in the United States. Some refineries rely on cheaper Canadian heavy crude oil, and there are few other options. The impact of rising costs is particularly severe in the Midwest of the United States, where nearly half of the crude oil used by fuel producers to produce gasoline and diesel comes from Canada.Xia Yiping, CEO of Extreme Vietnam: I won't run away! Agreeing with employees' reasonable demands, communication with Baidu and Geely working groups has been established. The reporter learned from the inside of Extreme Yue Automobile that on the evening of December 12, Xia Yiping, CEO of Extreme Yue Automobile, informed all employees of the latest progress by means of synchronous news of flying books. Xia Yiping said: "Shanghai, the social security provident fund tax payment is completed; Beijing Jidu Technology has paid the provident fund before, because the system can't pay the social security tax tonight (December 12), and will go to the counter to pay it early tomorrow (December 13); Beijing jidu service, social security provident fund tax payment is completed; Wuhan, the social security provident fund tax payment is completed; Zhejiang, the provident fund has been paid before, and the social security tax will be paid tomorrow (December 13); In the remaining cities, the social security provident fund has been paid, and the individual tax will be paid tomorrow (December 13). " (national business daily)CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.
To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)The organization looks forward to the semiconductor industry in 2025: the AI replacement tide leads the growth, and the semiconductor ETF(512480) may usher in new development opportunities. On December 13, the semiconductor ETF(512480) closed down by 1.38%, with a turnover of 1.671 billion yuan. The constituent stocks are mixed, and Zhaoyi Innovation leads the rise. In terms of decline, SMIC led the decline. CICC said that after the boom in 2024, it is expected that the inventory of the semiconductor industry will stabilize and the relationship between supply and demand will be more balanced in 2025. With the gradual landing of AI cloud and end demand, domestic semiconductor elements will usher in new development opportunities. In addition, the AI-changing tide has a pulling effect on the downstream demand of the semiconductor design sector, which is expected to accelerate the growth of the semiconductor design sector in 2025 and inject new vitality into the industry.Centaline Property: The price of second-hand houses in Hong Kong dropped by 0.6% on a weekly basis. Centaline Property said on its website that in the week from December 2 to 8, the leading index of Central Plains cities, which measures the price of second-hand houses in Hong Kong, fell by 0.6% to 137.59.
Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Shanghai Electric established a new company including machinery and equipment sales business. According to the enterprise search APP, Shanghai Dixi New Energy Co., Ltd. was established with Ye Can as its legal representative and registered capital of 1 million yuan. Its business scope includes: power generation business, power transmission business and power supply (distribution) business; Installation, maintenance and testing of power transmission, power supply and power reception facilities; Mechanical equipment sales; Mechanical and electrical equipment sales, etc. Enterprise survey shows that the company is wholly owned by Shanghai Electric New Energy Development Co., Ltd., a subsidiary of Shanghai Electric.Kunlun Unicom and Anheng Information signed a cooperation agreement. On December 11th, Beijing Kunlun Unicom Technology Development Co., Ltd. and Anheng Information signed a cooperation agreement for Beijing regional general generation in Beijing. In this cooperation, Kunlun Unicom will rely on Anheng Information's professional technology and products in the field of digital security to further enrich its solution system and provide customers with more comprehensive information technology services. At the same time, Anheng Information will also rely on Kunlun Unicom's extensive customer resources and market channels to expand its market business in Beijing.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14